Mixed
Network meta-analyses (NMA) provide superior clinical utility for diabetes management compared to standard pairwise meta-analyses by simultaneously comparing multiple treatments using both direct and indirect evidence.
When choosing between multiple diabetes medications (like SGLT-2 inhibitors, GLP-1 RAs, or finerenone), rely on Network Meta-Analyses (NMA) rather than single-trial results. NMAs allow you to compare all options simultaneously against standard care, revealing which drugs best reduce specific risks like heart failure or kidney disease for your patient's specific profile.
The use of network meta-analyses (NMA) can fill this need... NMAs combine direct and indirect evidence acquired from one or more common comparators to simultaneously compare multiple treatments in a single pooled analysis.
Why this rating
Based on a systematic review of 821 trials and 471,815 patients, graded using GRADE.
Source
Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop
Antonio Ceriello et al. · Cardiovascular Diabetology · 2023
DOI 10.1186/s12933-023-01993-3
More from this paper
- SGLT-2 inhibitors and GLP-1 receptor agonists significantly reduce major adverse cardiovascular events (MACE) and end-stage kidney disease (ESKD) in Type 2 Diabetes patients, with SGLT-2i showing specific superiority for kidney outcomes.Strong
- Tirzepatide (a dual GIP/GLP-1 receptor agonist) facilitates the largest reduction in body weight and increases in health-related quality of life (QoL) among Type 2 Diabetes medications.Strong
- Finerenone (a non-steroidal mineralocorticoid receptor antagonist) reduces hospital admissions for heart failure and end-stage kidney disease, and decreases mortality in Type 2 Diabetes patients with Chronic Kidney Disease (CKD).Good
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →